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Abstract
Background: Following successful eradication of wild polioviruses and planned globally-coordinated cessation of
oral poliovirus vaccine (OPV), national and global health leaders may need to respond to outbreaks from
reintroduced live polioviruses, particularly vaccine-derived polioviruses (VDPVs). Preparing outbreak response plans
and assessing potential vaccine needs from an emergency stockpile require consideration of the different national
risks and conditions as they change with time after OPV cessation.
Methods: We used an integrated global model to consider several key issues related to managing poliovirus risks
and outbreak response, including the time interval during which monovalent OPV (mOPV) can be safely used
following homotypic OPV cessation; the timing, quality, and quantity of rounds required to stop transmission;
vaccine stockpile needs; and the impacts of vaccine choices and surveillance quality. We compare the base case
scenario that assumes aggressive outbreak response and sufficient mOPV available from the stockpile for all
outbreaks that occur in the model, with various scenarios that change the outbreak response strategies.
Results: Outbreak response after OPV cessation will require careful management, with some circumstances
expected to require more and/or higher quality rounds to stop transmission than others. For outbreaks involving
serotype 2, using trivalent OPV instead of mOPV2 following cessation of OPV serotype 2 but before cessation of
OPV serotypes 1 and 3 would represent a good option if logistically feasible. Using mOPV for outbreak response
can start new outbreaks if exported outside the outbreak population into populations with decreasing population
immunity to transmission after OPV cessation, but failure to contain outbreaks resulting in exportation of the
outbreak poliovirus may represent a greater risk. The possibility of mOPV use generating new long-term poliovirus
excretors represents a real concern. Using the base case outbreak response assumptions, we expect over 25 %
probability of a shortage of stockpiled filled mOPV vaccine, which could jeopardize the achievement of global polio
eradication. For the long term, responding to any poliovirus reintroductions may require a global IPV stockpile.
Despite the risks, our model suggests that good risk management and response strategies can successfully control
most potential outbreaks after OPV cessation.
Conclusions: Health leaders should carefully consider the numerous outbreak response choices that affect the
probability of successfully managing poliovirus risks after OPV cessation.
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Background
As the areas of endemic wild poliovirus (WPV) circulation
shrink and the numbers of cases decline globally, focus
continues to shift toward the polio endgame [1]. Preparing
for oral poliovirus vaccine (OPV) cessation and managing
potential outbreaks emerge as critical activities [2]. The
Global Polio Eradication Initiative (GPEI) recognizes the
need to develop outbreak response plans for the polio
endgame as a priority [1], but efforts to date remain pri-
marily qualitative.
Prior analysis of outbreak response strategies for polio
demonstrated the importance of rapid detection and re-
sponse [3]. Another analysis showed the importance of
sufficiently high population immunity to transmission
prior to OPV cessation to prevent the subsequent forma-
tion of circulating vaccine-derived polioviruses (cVDPVs)
[4]. This study also demonstrated that responding with
monovalent OPV (mOPV) to a cVDPV outbreak that
occurs shortly after homotypic OPV cessation in a closed
model outbreak community does not lead to continued
circulation of the introduced OPV virus if the outbreak
response shuts down the outbreak virus [4]. However,
outbreak response planning efforts need to consider the
potential risks of exporting into other areas either the
outbreak virus or the OPV virus used for outbreak re-
sponse. In this context, the timing of a virus reintroduc-
tion after global OPV cessation and the resulting
accumulation of individuals who can contribute to trans-
mission in the event of an outbreak will likely affect de-
cisions related to using a live virus (i.e., mOPV) versus
inactivated poliovirus vaccine (IPV) for outbreak re-
sponse. A recent integrated global model (i.e., the global
model) explored the health and economic outcomes as-
sociated with phased OPV cessation of the three polio-
virus serotypes with different policies with respect to
IPV use [2]. The global model deterministically charac-
terized OPV evolution and the emergence of cVDPVs
and stochastically simulated potential reintroductions
from immunodeficiency-associated vaccine-derived po-
lioviruses (iVDPVs) and (un)intentional releases [2]. The
model assumed a very aggressive outbreak response
strategy involving 4–6 rounds (and more if transmission
continued) with serotype-specific mOPV during the first
5 years after homotypic OPV cessation, or IPV more
than 5 years after homotypic OPV cessation [2]. The
geographical scope of the outbreak response included
the outbreak population of approximately 10 million
people for settings with a basic reproduction number
(R0) for serotype 1 WPV (WPV1) of up to 9. For areas
with higher inherent poliovirus transmissibility (i.e., R0
for WPV1 > 9), the outbreak response area included the
approximately 10 million people in the outbreak popula-
tion and 9 connected populations each with approxi-
mately 10 million people. For all outbreak response
efforts, the targeted age groups increased as a function
of time since homotypic OPV cessation [2]. With a re-
sponse delay of 45 days after the initial outbreak detec-
tion, the outbreak response strategy successfully stopped
all outbreaks in 98 out of a set of 100 stochastic itera-
tions (i.e., realizations of random poliovirus reintroduc-
tions and exportations between populations) for a policy
involving at least one IPV routine immunization (RI)
dose for at least 5 years after cessation of all regular
OPV use (i.e., policy abbreviation IPV5) [2]. A related
analysis of vaccine needs demonstrated the linkage be-
tween pre-OPV cessation vaccine usage and expected
vaccine needs from the stockpile to respond to cVDPV
outbreaks [5].
The GPEI developed a qualitative matrix of outbreak re-
sponse plans based on the endgame phase (i.e., <2 years,
3–5 years, and >5 years since coordinated OPV cessa-
tion) and area where the outbreak occurs [6]. Specif-
ically, the GPEI recognized areas with a clear history
of sustained WPV transmission or the development of
cVDPV outbreaks as high-risk, areas with consistently
low immunization coverage and/or demonstrated
compromised population immunity to disease based
on a history of importation of WPV as medium-risk,
and areas with consistently higher coverage and few
risk factors for sustained transmission of poliovirus as
relatively low-risk. This analysis uses the global model
to explore a number of outstanding questions related
to outbreak response after OPV cessation, including
the role of key outbreak response choices (i.e., timeli-
ness of detection and response, quality, scope, and
number of rounds, vaccine type) and stockpile vaccine
needs.
Methods
This section first briefly explains essential concepts from
the global model needed to interpret the outbreak
response analyses in this paper, with key numerical
assumption provided in Table 1. The next subsection
describes the approach for the outbreak response ana-
lyses and the remaining subsections detail each outbreak
response option we considered.
Global model concepts
The global model [2] integrates a characterization of the
variability in conditions and mixing between populations
with a differential equation-based model (i.e., the DEB
model) of poliovirus transmission and OPV evolution for
each population, and stochastic models of poliovirus rein-
troductions after OPV cessation. The global model divides
the world into 710 subpopulations of approximately 10
million people, grouped into epidemiological blocks con-
sisting of 10 subpopulations each that mix preferentially
with each other. We characterize each population using
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Table 1 Overview of key numerical assumptions of the models used
Assumption Value Sourcea
DEB model (Values based on expert review [12, 21, 22] and model calibration [9, 10] process)
Relative contribution to transmission compared to fully susceptible, by immunity stateb [9, 17]
Maternally immune 0.66;0.48
1 successful IPV dose, recent 0.74;0.41
1 successful IPV dose, last waning stage 0.90;0.36
2 successful IPV doses, recent 0.42;0.06
2 successful IPV doses, last waning stage 0.81;0.13
≥ 3 successful IPV doses, recent 0.28;0.04
≥ 3 successful IPV doses, last waning stage 0.72;0.06
1 LPV infection, recent 0.07;0.05
1 LPV infection, last waning stage 0.20;0.20
≥ 2 LPV infections or IPV and LPV (any # or order), recent 0.01;0.01
≥ 2 LPV infections of IPV and LPV (any # or order), lastwaning stage 0.08;0.06
Average time for maternally immune newborns to wane to fully susceptible [months] 3 [9]
Average time for other immunity states to wane from recent to fifth and last waning stage [years] [9]
Serotypes 1 and 2 4
Serotype 3 3




Relative R0 compared to serotype 1 R0 [9]
Serotype 2 0.9
Serotype 3 0.75




Average time to reach last of 20 reversion stages (i.e., fully-reverted VDPV, with same properties as homotypic WPV) [years] [9, 10]
Serotype 2 1.1
Serotypes 1 and 3 1.7
Transmission threshold, i.e., minimal prevalence (weighed by contribution to transmission) for non-zero force-of-infection
[effective infectious proportion]
5 per million [9]
Global model [2]
Timing of major events
bOPV introduction for some SIAs 2010
IPV introduction (in populations using OPV-only in 2013) 2015
tOPV intensification (until OPV2 cessation) 2015
OPV2 cessation (in April) 2016
OPV13 cessation (in April) 2019
Last year when all populations use IPV 2024
Last full year of analytical time horizon (Tend) 2052
Average per-dose take rate for OPVd [%] [2, 24]
tOPV, serotype 1 35–65
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Table 1 Overview of key numerical assumptions of the models used (Continued)
tOPV, serotype 2 60–75
tOPV, serotype 3 27–55
mOPV, serotype 1 45–90
mOPV, serotype 2 60–95
mOPV, serotype 3 45–85
bOPV, serotype 1 42–80
bOPV, serotype 3 42–80
Average per-dose take rates for IPV (any serotype)e [%] [2]
Low- and lower-middle income populations 63
Upper middle-income populations 70
High-income populations 75
Number of subpopulations with given R0 for WPV1

















RI coverage and schedules Variesh [2]
Preventive SIA impact and schedules Variesi [2, 5]
Cumulative effective infections needed to trigger a potential exportation from a subpopulation (exportation threshold) 200,000 [2]
iVDPV prevalence Variesj [7]
Average time between contacts of long-term iVDPV excretors with the general population [days] 150–600 [2]
Global rate of WPV and Sabin seed strain releases from randomly determined IPV production sites [per year] 1/5 [2]
Other poliovirus releases (i.e., inadvertent OPV use, unintentional release from laboratory, intentional release) Variesk [2]
Abbreviations: bOPV bivalent oral poliovirus vaccine of serotypes 1 and 3, DEB model differential equation-based poliovirus transmission and OPV evolution model,
IPV inactivated poliovirus vaccine, iVDPV immunodeficiency-associated vaccine-derived poliovirus, LPV live poliovirus, mOPV monovalent OPV, OPV oral poliovirus
vaccine, OPV## cessation globally-coordinated cessation of OPV containing the serotype(s) indicated by ##, PID primary immunodeficiency disease, RI routine
immunization, R0 basic reproduction number, SIA supplemental immunization activity, Tend end of the analytical time horizon (i.e., December 31, 2052), tOPV
trivalent OPV, WPV(1,2,3) wild poliovirus (serotype 1, 2, or 3, respectively)
aPublications that list the numerical assumption and/or provide methodological details
bNumbers separate by semi-colons indicate contribution to a fecal-oral and oropharyngeal transmission, respectively
cModel assumes half of these ratios for maternally immune individuals and full and permanent protection from paralysis in all other immunity states
dValues vary by population and correlate with higher R0 values
eIncludes priming response without seroconversion for first IPV dose
fR0 values for OPV and VDPV/WPV of each serotype follow from relative R0 values in top section of table
gLower values correlate with higher R0 values
hSee source for values by subpopulation; technical details about characterization of RI provided in [9, 25]
iSee sources for values by subpopulation; technical details about characterization of SIAs provided in [10]
jGenerated by discrete-event simulation model of all global PID patients [7]
kDepends on nature of release, income level, and time
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pre-defined assumptions about poliovirus transmissibility
(i.e., basic reproduction numbers (R0 values) for each virus
strain, which directly relate to the assumed R0 for WPV1
in the population using relative R0 values), the relative im-
portance of fecal-oral and oropharyngeal transmission
(which affects the impact of IPV use on transmission),
OPV and IPV take rates, immunization history and inten-
sity going forward (e.g., RI coverage, SIA frequency and
quality), surveillance quality (i.e., number of cumulative
paralytic cases to trigger detection of an outbreak), and
age-heterogeneity in mixing.
All global model runs assume the same run-up until
2013, after which the results depend on long-term polio-
virus risk management policies and random events.
Long-term poliovirus risk management policies run
through 2052 and include OPV cessation with different
durations of IPV use. The main policy option remains
consistent with the Global Polio Eradication Initiative
Strategic Plan 2013–2018 [1] and assumes globally-
coordinated cessation of serotype 2-containing OPV
(OPV2 cessation) in 2016, globally-coordinated cessation
of serotype 1- and 3-containing OPV (OPV13 cessation)
in 2019, and 5 subsequent years in which all populations
use at least one IPV RI dose (i.e., IPV5).
cVDPV outbreaks occur deterministically in the model
depending on population immunity at and beyond OPV
cessation, but all other potential poliovirus reintroductions
(from iVDPVs, IPV productions sites, inadvertent OPV
use, or other unintentional or intentional releases) occur
randomly. A discrete-event simulation model estimates
the prevalence of primary immunodeficiency disease
patients with long-term iVDPV infections, including any
patients infected with OPV used for outbreak response
after OPV cessation [7]. Potential poliovirus exportations
occur whenever a threshold number of infections accu-
mulate in a subpopulation as a result of exposure to the
outbreak virus or OPV used to respond to it, with the
destination populations determined randomly.
Transmission of a poliovirus in the DEB model only
occurs when the effective prevalence of that poliovirus re-
sides above the transmission threshold. Thus, an outbreak
may die out within a subpopulation if natural immunity
derived by the outbreak virus and/or immunity derived by
the outbreak response drives the prevalence below the
transmission threshold. Similarly, depending on popula-
tion immunity to poliovirus transmission in a polio-free
subpopulation, potential poliovirus reintroductions or
importations may or may not generate enough initial
transmissions to exceed the transmission threshold and
start to circulate at the subpopulation level. We model this
by specifying a function for the probability that an intro-
duction becomes “effective”. Specifically, the probability
increases with the net reproduction number (Rn), defined
as the average number of secondary infections generated
by each new infection, taking into account both the R0 of
the virus and the population immunity level and mixing
[8]. If Rn > 1, then the poliovirus can circulate in a popula-
tion, and the growth rate of the outbreak increases as Rn
increases. To calculate Rn, we account for the relative R0
for the WPV serotype, the serotype-specific relative R0 for
OPV compared to homotypic fully-reverted VDPV (i.e.,
assuming the same R0 as homotypic WPV, which implies
relative values of 1:0.9:0.8 for VDPV and WPV serotypes
1, 2, and 3, respectively), and the seasonal variation in
poliovirus transmissibility [2, 9, 10].
Due to random events, each stochastic iteration of the
global model produces a different possible future, and
therefore we based economic estimates of long-term
poliovirus risk management policies on the average of a
set of 100 stochastic iterations [2]. In the event of un-
controlled outbreaks, paralytic polio cases will continue
to accumulate after OPV cessation. If this leads to at
least 50,000 paralytic polio cases, then the global model
assumes that all populations that used OPV as of 2013
would resume OPV use, which we refer to as OPV re-
starts. In this study, we assume that all OPV restarts re-
sume OPV in RI but not in SIAs.
Analytical approach
Table 2 lists the outbreak response assumptions for all
policies analyzed in the global model base case [2] and
alternative choices explored in this study. All analyses
assume the same main long term global poliovirus risk
management policy of at least 5 years of IPV use after
OPV13 cessation in all populations, but they vary the
outbreak response assumptions. The analyses repeat one
or more of the 100 global model iterations for each
outbreak response choice. Table 2 does not include
choices about the duration of each outbreak response
SIA (oSIA), which we fixed at 5 days, or the target age
groups (i.e., 0–4 years between 0 and 4 years after
homotypic OPV cessation, 0–9 years between 5 and 9
years after homotypic OPV cessation, 0–14 years be-
tween 10 and 14 years after homotypic OPV cessation,
etc.), which we did not vary in this analysis. As shown in
the last two columns of Table 2, we examined the impact
of each outbreak response choice by looking at the
behavior for specific examples, or by examining global
model outputs for the full set of 100 iterations, or both,
depending on the outcomes of interest and computa-
tional resource requirements. When examining outputs
for the full set of iterations, we consider all iterations
affected by each change from the set of 100 iterations
for the IPV5 policy (Table 2). For example, reducing the
duration of mOPV use for oSIAs after homotypic OPV
cessation from 5 to 3 years only affects 77 iterations in
which at least one outbreak response occurs from 3 to 5
years after homotypic OPV cessation.
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Initial number of oSIAs. oSIA impact level, and interval
between oSIAs
Upon outbreak detection in a subpopulation, the base
case outbreak response strategy conducts between 4 and
6 high-quality oSIAs, depending on the subpopulation
R0, with a block-wide response if the detection occurs in
a subpopulation with an R0 of 10 or more (Table 2). An
additional series of 4–6 oSIAs may occur in the event of
a detection of a case after the last oSIA in a series. We
characterize oSIA quality using three oSIA impact levels
that represent different combinations of true coverage
(i.e., the overall proportion of targeted individuals receiv-
ing a dose), and repeated missed probability (i.e., the
proportion of individuals targeted but missed by the pre-
vious SIA who again do not receive a dose). To explore
how the choice of the initial number of oSIAs interacts
with the quality of the oSIAs, we simultaneously varied
both parameters and focused on their impact on the be-
havior of an outbreak that occurs in a block with a very
high R0 of 13 following a serotype 1 iVDPV (iVDPV1)
introduction. For the same outbreak, we also considered
the interaction between the initial number of oSIAs and
the interval between each oSIA in a series, which equals
30 days for the base case.
Mixed IPV/OPV use (ring)
We selected two stochastic iterations to explore the po-
tential strategy of conducting outbreak response with
mOPV in the outbreak population, and a ring of IPV in
surrounding populations, which we operationalized in
the model as mOPV use in any subpopulation with a
detected case and IPV use in all other subpopulations of
the same block.
Duration of mOPV use after homotypic OPV cessation
The base case outbreak response strategy assumes
mOPV use only for 5 years after global homotypic OPV
cessation to avoid reintroducing large amounts of LPV
at a time of globally much-decreased population immun-
ity, with IPV use for any subsequent oSIAs. We explored
the impact of different durations of mOPV use on effect-
ive mOPV exportations, new iVDPV infections, and
Table 2 Outbreak response choices considered
Outbreak response choice Base case Alternative(s) Iterations considered Outcomes of interest
Initial number of oSIAsa 4 (R0 < 12) 3, 4, 5, 6, or 7 1 selected iteration Behavior
6 (R0 ≥ 12)
oSIA impact levelb,c B A, B, or C 1 selected iteration Behavior
Interval between oSIAs (days)c 30 15 1 selected iteration Behavior




Selected iterations Behavior, mOPV exportations,
new iVDPV excretors,
OPV restarts
Duration of mOPV use after
homotypic OPV cessation (years)
5 3, 10, 20, or through
Tend




(minimum R0 to trigger
block-wide response)
10 8 or 13 All affected Effective mOPV exportations;
new iVDPV excretors; OPV restarts
Response delay (days)d and
detection thresholde
Delay 45 and threshold
variable (initial detection)
or delay 30 and threshold 1
(oSIAs ongoing in block)
Delay always 30, 45,
or 50 and threshold
always variable
All affected Behavior; OPV restarts
Serotype 2 vaccine between
OPV2 and OPV13 cessation
Serotype 2 mOPV tOPV, IPV All affected +1 iteration
without tOPV intensification
Population immunity; number
and size of outbreak; OPV restarts
Finite mOPV stockpile Unlimited stockpiles 100 million filled and
400 million bulk doses
of each mOPV serotype
All affected Behavior; OPV restarts
Abbreviations: IPV inactivated poliovirus vaccine, iVDPV immunodeficiency-associated vaccine-derived poliovirus; mOPV, monovalent OPV, OPV## cessation,
globally-coordinated cessation of OPV containing the serotype(s) indicated by ##, OPV oral poliovirus vaccine, oSIA outbreak response supplemental immunization
activity, R0 basic reproduction number, Tend end of the analytical time horizon (i.e., December 31, 2052), tOPV trivalent OPV
aConsidered jointly with oSIA impact level and interval between oSIAs
bKey for SIA impact levels: A = true coverage of 0.5 and repeated missed probability if 0.8; B = true coverage of 0.8 and repeated missed probability if 0.7; C = true
coverage of 0.95 and repeated missed probability if 0.5
cConsidered jointly with initial number of oSIAs
dTime between detection and first day of first oSIA
eCumulative number of paralytic cases per 10 million people to trigger a detection
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OPV restarts (Table 2). For further context on the time
interval during which mOPV can be safely used for
oSIAs, we report for the base case outbreak response
strategy the fraction of subpopulations for which the Rn
of OPV of each serotype exceeds 1 as a function of time.
As Rn increases, both the probability of an effective
mOPV introduction as a result of an mOPV exportation
and the consequences of an effective mOPV introduc-
tion increase.
Geographical scope
We consider the impact of the minimum R0 that triggers
a block-wide response on effective mOPV exportations,
new iVDPV infections, and OPV restarts (Table 2).
Response delay and detection threshold
In the event of a subpopulation-specific outbreak re-
sponse, the base case strategy assumes that all other
subpopulations in the same block remain on “high alert”
for surveillance and response until the last oSIA in the
block, which leads to a low detection threshold of one
paralytic case and a shorter response delay of 30 instead
of 45 days (Table 2). We considered the impact of not
moving the neighboring subpopulations to “high alert”
and also varied the response delay between 30 and 60
days while keeping the detection threshold unaffected by
the ongoing oSIAs.
Serotype 2 vaccine
In the event of serotype 2 outbreaks between OPV2 cessa-
tion and OPV13 cessation, using trivalent OPV (tOPV) in-
stead of mOPV2 could raise population immunity to
transmission for serotypes 1 and 3 before OPV13 cessation.
Although logistical and regulatory constraints may compli-
cate tOPV use after OPV2 cessation, we explored the use
of tOPV for outbreak response instead of mOPV2 by
characterizing the changes in population immunity to
transmission for all 3 serotypes, and the number of OPV
restarts. Given current discussions to use IPV in response
to cVDPV2 outbreaks, we further considered the option of
using IPV instead of mOPV2 or tOPV for outbreaks that
occur between OPV2 and OPV13 cessation. To explore
cVDPV2 outbreak and population immunity behavior for
these vaccine choices, we ran the model without tOPV in-
tensification prior to OPV2 cessation and considered the
resulting outbreak.
Stockpile choices
The base case response assumes no constraints on the
amount of vaccine available for oSIAs from a stockpile. In
reality, the GPEI plans to hold approximately 100 million
filled and 400 million bulk mOPV doses of each serotype.
To further stockpile planning, we report the expected
mOPV and IPV stockpile needs for each serotype as a
function of time after homotypic OPV cessation for the
base case outbreak response strategy based on all 100 iter-
ations. To estimate stockpile vaccine needs, we multiply
the targeted population of each oSIA by an effective wast-
age factor that conservatively accounts for demographic
uncertainty [2, 5]. We further explore the potential conse-
quences of the currently planned mOPV stockpile for all
iterations in which a stock-out would occur given the cur-
rently planned filled and bulk mOPV stocks, with all other
assumptions as in the base case response strategy. To
determine when a stock-out of readily available filled
mOPV would occur, we assume that new orders to con-
vert bulk to filled vaccine occur on the first day of each
oSIA, leading to a one year filling delay with a “pipeline
delay”, so that all newly-ordered filled vaccine arrives
exactly one year after placing the order [11]. For
simplicity, these analyses conservatively assume no
prioritization of the mOPV in case of a shortage and as-
sume that any IPV oSIAs will not occur until after clos-
ure of the 5-year mOPV use window. For all of the
analyses in Table 2, we consider how the stockpile
needs change in addition to the other outcomes of
interest listed in Table 2.
Results
This section presents the results related to each out-
break response choice in separate subsections.
Initial number of oSIAs. oSIA impact level, and interval
between oSIAs
Figure 1 shows the outbreak behavior for different com-
binations of quality and initial quantity of oSIAs and for
different intervals between oSIAs. The outbreak in this
selected iteration originates from an iVDPV1 introduc-
tion soon after OPV13 cessation in a block with the
highest R0 in the global model (i.e., R0 = 13 for WPV1).
Due to the high R0, the model assumes a block-wide
outbreak response. Figure 1a shows that in this popula-
tion, low quality oSIAs (i.e., true coverage of 50 % per
round and repeated missed probability of 80 %) do not
control the outbreak, even if the response involves 7
oSIAs at 30-day intervals in each series. Failure to con-
tain the outbreak eventually results in exportations to
other blocks with low population immunity to transmis-
sion and a need to restart OPV use after more than
50,000 paralytic cases accumulated since 2016. For the
base case response strategy quality level (i.e., true cover-
age of 80 % per round and repeated missed probability
of 70 %), control of the outbreak becomes possible with
6 or more oSIAs per series but not with 5 or fewer
oSIAs per series (Fig. 1b). However, the initial series
does not prevent a second peak later in 2020, and thus
die-out occurs only after two series of 6 or 7 oSIAs. Fur-
ther increasing the quality (i.e., true coverage of 95 %
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per round and repeated missed probability of 50 %) sig-
nificantly improves performance, with two series of 4 or
more oSIAs successfully containing the outbreak.
Figure 1d shows that shortening the interval between
oSIAs in a series from 30 to 15 days somewhat affects
the kinetics of the outbreak compared to Fig. 1b, but
does not change the minimum of 6 oSIAs needed per
series to control the outbreak.
Mixed IPV/OPV use (ring)
Figure 2 shows two contrasting examples of outbreaks
involving different ring strategies. The base case re-
sponse strategy assumes block-wide response with
mOPV following detection of the outbreak virus in any
of its subpopulations. The IPV ring strategy assumes
mOPV use in the subpopulation that detected the out-
break and IPV use in the other 9 subpopulations of its
block, while the third strategy assumes no oSIAs in
other subpopulations until they detect virus. In the first
example, the base case, block-wide mOPV response
strategy contains the outbreak in the subpopulation that
experiences the introduction (Fig. 2a, solid curve). In
contrast, with a subpopulation-specific response, expor-
tations of the outbreak virus to other subpopulations in
the same block can take off, leading to new outbreaks
that trigger further subpopulation-specific oSIAs (Fig. 2a,
dashed curve). In this stochastic realization of export-
ation events, a serotype 2 mOPV (mOPV2) virus used
in one of the secondarily affected subpopulations
establishes transmission in a block with a WPV1 R0 of
13 in which the population immunity to transmission
decreased so much after OPV2 cessation that it can sup-
port transmission of even the attenuated mOPV2 virus.
With successive chains of transmission, this virus even-
tually evolves to a cVDPV2 and triggers an OPV restart.
Using mixed mOPV2 in the outbreak subpopulation and
Fig. 1 Outbreak and response behavior for different initial number of outbreak response supplemental immunization activities (oSIAs), oSIA
quality, and oSIA interval assumptions for an outbreak in a high basic reproduction number population, showing the incidence in the block of the
initial outbreak. a oSIA impact level A (i.e., true coverage of 0.5 and repeated missed probability* of 0.8). b oSIA impact level B (i.e., true coverage of 0.8
and repeated missed probability of 0.7). c oSIA impact level C (i.e., true coverage of 0.95 and repeated missed probability of 0.5). d oSIA impact level B
(i.e., true coverage of 0.8 and repeated missed probability of 0.7), but with 15 instead of 30 days between oSIAs. * The repeated missed probability
represents the proportion of targeted individuals missed by an SIA who were targeted and missed by the previous SIA [10]
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IPV in the other 9 subpopulations prevents this from oc-
curring (Fig. 2a, dotted curve). Although the IPV oSIAs
do not completely prevent the secondary outbreaks they
keep the outbreaks smaller and fewer in number. Thus,
in this example, the IPV ring works not because it
contains the mOPV2 used in the initial response, but
because it prevents the need for some secondary
subpopulation-specific oSIAs that otherwise become
problematic.
In the second example, a different problem occurs as a
result of mOPV use during oSIAs. The base case, block-
wide mOPV1 response strategy to an iVDPV1 outbreak
successfully controls the outbreak (Fig. 2b, solid curve).
However, in the realization of the risks, a patient with
PID and prone to long-term poliovirus infection
acquires an mOPV1 infection in one of the subpopula-
tions not directly affected by the outbreak that conducts
a pre-emptive mOPV1 oSIA as part of the block-wide
Fig. 2 Two contrasting examples of serotype 1 and 2 immunodeficiency-associated vaccine-derived poliovirus (iVDPV1 and iVDPV2, respectively) outbreaks
with various outbreak response vaccine choices for subpopulations that share a block with subpopulations that detected a case , including a ring with
inactivated poliovirus vaccine (IPV), showing the incidence in the block of the initial outbreak. a Outbreak following an iVDPV2 introduction in a block with
a basic reproduction number (R0) of 10, resulting in a serotype 2 monovalent oral poliovirus vaccine (mOPV2) exportation outbreak in another block for
the strategy that responds only in subpopulations with detected virus using mOPV2. b Outbreak following an iVDPV1 introduction in a block with an R0 of
11, resulting in a new iVDPV1 excretor and virus reintroduced for the strategy of serotype 1 monovalent oral poliovirus vaccine (mOPV1) in the entire block
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response strategy. This new iVDPV1 excretor re-
introduces the virus years later, at which point the model
no longer assumes mOPV1 availability for outbreak
response. The subsequent IPV oSIAs fail to control the
outbreak, and thus this iteration ultimately leads to one
of the two OPV restarts that we observed for the base
case. In this example, the subpopulation-specific out-
break response (with or without the IPV ring) suffices to
control the outbreak and avoids the mOPV1 infection
that generates the new iVDPV1 excretor. We emphasize
that both examples in Fig. 2 depend on rare stochastic
events (i.e., initial iVDPV introductions, effective OPV
exportations, and new iVDPV infections and introduc-
tions) that we did not observe in other iterations with
the base case. However, the possible behavior in Fig. 2
illustrates the dilemma associated with vaccine type and
oSIA scope decisions, with mOPV carrying some risk of
new events and IPV oSIAs carrying a substantial risk of
failing to control outbreaks.
Duration of mOPV use after homotypic OPV cessation
In the context of assessing the risk of exportation of
mOPV used during oSIAs, Fig. 3 shows the proportion
of all subpopulations in the model with low enough
population immunity to transmission to support trans-
mission of mOPV of each serotype (i.e., Rn > 1 for OPV)
as a function of time since homotypic OPV cessation.
The results differ by type primarily because of the differ-
ence in assumed relative R0 values of OPV compared to
homotypic WPV or VDPV (i.e., OPV2 > OPV1 >OPV3)
[9, 10, 12]. The results oscillate because of seasonal
changes in R0 and therefore in Rn [2, 13, 14]. Figure 3
suggests that within 2–3 years of OPV cessation, some
transmission may occur in the event of imported
mOPV2 and mOPV1 in some subpopulations, with little
risk of mOPV3 establishing transmission for at least
5 years after OPV cessation. However, with Rn only
slightly above 1 for some part of the year, such transmis-
sion may not result in a VDPV outbreak. Moreover,
potential mOPV exportations to other blocks occur rela-
tively rarely, and we assume that chance determines
whether potential exportations effectively establish
transmission beyond the initial contacts [2].
Table 3 includes results related to mOPV exportations
for the various outbreak response scenarios, summed
over all 100 iterations. For the base case, we find that
potential mOPV-related exportations occur regularly
(i.e., approximately 36 per stochastic iteration on aver-
age). Given that most of these occur during the first few
years after homotypic OPV cessation when population
immunity remains high in most subpopulations (Fig. 3),
only approximately 10 % of them result in effective
mOPV-related virus reintroduction. Due to the assumed
highly preferential mixing within blocks [2], over 95 % of
the effective exportations remain in the same block. The
block-wide response strategy in blocks with an R0 of 10
or more in the base case helps prevent most of these
exportations from evolving to VDPVs, while in lower-R0
blocks the Rn values for OPV-related viruses typically
remain low enough to prevent transmission. For the 14
effective exportations to other blocks that occurred in
the 100 iterations with the base case response strategy
(Table 3), none led to any outbreaks because the Rn
values all remained close to 1. The use of mOPV for
oSIAs also creates a risk of newly infecting PID patients
with potential long-term excretion, which occurred in
the simulations approximately once per iteration on
average. However, the majority of these occur in popula-
tions with higher R0 values, which account for most
mOPV oSIA doses and in which survival of PID patients
remains shortest [7]. Therefore, newly infected PID
patients only generate few potential iVDPV introduc-
tions (i.e., on average approximately one per excretor),
and most occur soon after the outbreak response when
population immunity to transmission remains high,
which prevents the potential iVDPV introductions from
becoming effective introductions or outbreaks. However,
10 of the 22 effective iVDPV introductions in the base
case resulted in a new outbreak of cases that required a
response. In one iteration, an outbreak due to a new
iVDPV excretor beyond the 5-year window of mOPV
use for outbreak response results in uncontrolled out-
breaks and an eventual OPV restart (see Fig. 2b). The
two iterations with an OPV restart by definition result in
very large numbers of expected cases, and therefore
drive the average expected number of cases based on all
100 iterations, which equals approximately 15,000.
Fig. 3 Proportion of subpopulations (n = 710) with a net
reproduction number (Rn) of oral poliovirus vaccine (OPV) of more
than 1 for a global model iteration with no outbreaks with the
global policy of at least 5 years of inactivated poliovirus vaccine in
all populations for 5 years after OPV cessation of the last serotype
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Out-breaks No OPV restart OPV restart All
Base case N/A 3,618 312 (14) 0 117 96 22 10 2 340 720,000 15,000
Duration of mOPV use
after homotypic OPV
cessation (years)
- 3 77 3,141 255 (11) 0 84 57 15 7 10b 240 850,000 85,000
- through Tend 30 4,153 364 (18) 0 136 119 23 19 0 370 - 370
Minimum R0 to trigger
block-wide response
- 8 45 5,709 479 (23) 0 173 151 34 16 2b 370 610,000 13,000
- 13 43 1,323 155 (12) 1 64 66 15 7 4 370 1,000,000 40,000
Response delay (days)c
- Always 30 96 3,521 300 (15) 0 106 99 23 10 2 240 530,000 11,000
- Always 45 92 3,620 311 (14) 0 117 96 22 10 3 620 1,000,000 29,000
- Always 60 96 3,936 335 (18) 0 133 106 23 10 6 640 1,100,000 64,000
oSIA vaccine between
OPV2 and OPV13
cessation for serotype 2
outbreaks
- tOPV 36 3,634 315 (5) 0 117 96 21 10 2 340 720,000 15,000
- IPV 36 3,586 317 (14) 1 121 96 22 11 3 360 740,000 22,000
Finite mOPV stockpile 27 3,962 347 (19) 0 166 102 24 10 7b 1,300 770,000 55,000
Abbreviations: IPV inactivated poliovirus vaccine, iVDPV immunodeficiency-associated vaccine-derived poliovirus; mOPV, monovalent OPV, OPV oral poliovirus vaccine, OPV## cessation globally-coordinated cessation
of OPV containing the serotype(s) indicated by ##, oSIA outbreak response supplemental immunization activity, PID primary immunodeficiency disease, R0 basic reproduction number, Tend end of the analytical time
horizon (i.e., December 31, 2052), tOPV trivalent OPV
aDoes not include a total of approximately 1,000 expected WPV, VAPP, and cVDPV cases that occur before OPV cessation of each serotype [2]
bOne additional iteration had ongoing LPV transmission at Tend without having accumulated 50,000 cases since 2016















Reducing the window of mOPV use from 5 to 3 years
after homotypic OPV cessation led to a clear reduction
in the number of mOPV exportations and newly
infected iVDPV excretors and associated events. How-
ever, with no mOPV use allowed to respond to new out-
breaks between 3 and 5 years after homotypic OPV
cessation or outbreaks not controlled within the first
3 years, control of these outbreaks (i.e., with IPV oSIAs)
becomes much more difficult. In this case, 8 additional
iterations resulted in an OPV restart for the 3-year
mOPV use window, which increased the average
expected number of cases from 15,000 to 85,000. Con-
versely, allowing mOPV use for oSIAs through the end
of the model time horizon (i.e., Tend) substantially
increased the number of mOPV exportations and new
iVDPVs. Although the population immunity levels over
5 years after OPV cessation of each serotype support
mOPV transmission in a large fraction of all subpopula-
tions in the model (Fig. 3), remarkably none of the
approximately 360 effective mOPV exportations or 23
effective iVDPV introductions resulted in uncontrolled
outbreaks. This reflects the location of the majority of
these effective exportations and introductions occurring
in subpopulations that benefit from higher population
immunity due to recent mOPV oSIAs. In the event of
outbreaks not controlled in the first subpopulation,
mOPV exportations sometimes occurred but resulted in
no independent outbreak events because the outbreak
virus got exported before or soon after the OPV virus
and caused cases before OPV evolved to a cVDPV.
Moreover, for any effective introductions that do lead to
outbreaks, including for the two iterations with an OPV
restart for the base case, the use of mOPV in response
to late outbreaks facilitates rapid control and containment
of these outbreaks. Intuitively, an aggressive outbreak re-
sponse strategy that limits propagation of a given outbreak
to one new block or fewer on average leads to the eventual
full control of the outbreak. For mOPV use in oSIAs
through Tend, this occurs in the global model despite the
risk of mOPV exportations and new iVDPV excretors.
Consequently, we observed no OPV restarts and the low-
est average expected number of cases for this outbreak re-
sponse strategy among all considered options. However,
we caution that the global model does not characterize
the mixing patterns at the border of the mOPV oSIA tar-
get population where exportations to other areas may
occur much more frequently than the average frequency
of exportations between populations.
Geographical scope
Increasing the geographical scope of the outbreak
response to include a block-wide response for all out-
breaks in populations with an R0 of 8 or more (instead
of 10 or more) led to more mOPV exportations and new
iVDPV introductions compared to the base case. How-
ever, these did not result in uncontrolled outbreaks or
new OPV restarts. To the contrary, the expanded scope
reduces the number of cases for the two iterations with
an OPV restart for the base case, which resulted in a
relatively small but notable reduction in the average
expected number of cases. Reducing the geographical
scope of the outbreak response reduced the risk of any
outbreaks due to mOPV exportations or new iVDPV
excretors, but led to a failure to control outbreaks in 2
additional iterations and thus a higher average expected
number of cases. One of these OPV restarts related to a
mOPV exportation that eventually caused new cVDPV
outbreaks after the 5-year period of mOPV use, as dis-
cussed in the context of Fig. 2b.
Response delay and detection threshold
The response delay affects the ability to contain out-
breaks before further spread. Therefore, we observed an
increase in the number of OPV restarts and average
expected number of cases as we increased the response
delay. The effect on mOPV exportations and new
iVDPV excretors remains moderate, with a slight
increase in these events for a slower response because
the slower response requires more oSIAs due to failures
to prevent outbreak virus exportations or to control the
outbreak after the initial oSIA series. Reducing the
response delay from 45 to 30 days significantly
decreased the average expected cases for both iterations
with and without an OPV restart. The choice of oSIA
vaccine for serotype 2 outbreaks affects population
immunity to transmission for the other two serotypes,
but did not much affect the overall results based on 36
affected iterations in Table 3. For the IPV option, this re-
lates to the assumption that the oSIA strategy reverts to
mOPV2 after OPV13 cessation, which allows control of
most uncontrolled serotype 2 outbreaks. Nevertheless, in
one iteration, the use of IPV for oSIAs before OPV13
cessation resulted in uncontrolled outbreaks and an OPV
restart, which increased the average expected number of
cases for this strategy. In another iteration, IPV oSIAs
failed to control a serotype 2 outbreak before switching
to mOPV2 oSIAs after OPV13 cessation, which resulted
in an mOPV2 exportation that required an outbreak
response but did not lead to an eventual OPV restart.
Serotype 2 vaccine
Figure 4 illustrates the behavior for the different sero-
type 2 oSIA vaccine choices, based on a run with insuffi-
cient tOPV intensification that results in a cVDPV2
outbreak within a year after OPV2 cessation (and no
other risks included in Fig. 4) [2, 5]. Outbreak responses
with tOPV or mOPV2 remain equivalent in terms of the
ability to rapidly control the outbreak due to assumed
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equal average per-dose take rates for serotype 2 in the
affected population (Fig. 4a) [2]. In contrast, the 4 IPV
oSIAs in the outbreak block fail to fully control the
outbreak, which leads to a second outbreak wave in 2019
that eventually gets controlled by assumed mOPV2 use
for oSIAs following OPV13 cessation in 2019. Figure 4b
shows the clear benefit of tOPV over mOPV2 with
respect to sustaining high population immunity to sero-
type 1 and 3 transmission for the duration of the outbreak
response, which the model assumes suspends any planned
preventive SIAs with serotype 1 and 3 bivalent OPV.
IPV oSIA also sustain some population immunity to
transmission, but not as much as tOPV, and this benefit
trades off poorly against the inability of IPV to control the
cVDPV2 outbreak that triggered its use. The increase in
population immunity to serotype 2 transmission for the
IPV oSIAs curve during 2019 reflects the second outbreak
wave that occurs with that outbreak response strategy.
Stockpile choices
Figure 5 shows the cumulative oSIA vaccine needs based
on all 100 iterations of the global model with IPV5 and
the base case response strategy and accounting for sig-
nificant assumed wastage. The averages and medians in
Fig. 4 Example of outbreak response supplemental immunization activity (oSIA) choices to a serotype 2 circulating vaccine-derived poliovirus
(cVDPV2) outbreak that occurs after serotype 2 oral poliovirus vaccine (OPV) cessation without prior triavelent OPV (tOPV) intensification, using
serotype 2 monovalent OPV (mOPV2), tOPV, or inactivated poliovirus vaccine (IPV). a Incidence of paralytic poliomyelitis cases (in the block of the
cVDPV2 outbreak). b Population immunity to transmission for all 3 serotypes, expressed as the mixing-adjusted immune proportion (EIPM) in the
subpopulation of the cVDPV2 outbreak
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Fig. 5 remain well below the currently planned 100
million filled doses for each mOPV serotype. However,
32 stochastic iterations require more than 100 million
mOPV doses for at least one serotype (i.e., 23 for
mOPV1, 12 for mOPV2, 8 for mOPV3) and the maxima
for mOPV1 and mOPV3 both exceed the total planned
bulk and filled stockpile of 500 million doses. While
these represent outliers from the distribution, they sug-
gest some risk of insufficient stockpiled vaccine to meet
the expected demand for the base case response strategy.
With respect to the IPV stockpile vaccine needs, we
similarly observe one outlier that involves repeated IPV
oSIAs that fail to control an outbreak but do prevent the
total number of cases from reaching the 50,000 thresh-
old that would trigger OPV restart for many years.
While this outlier explains the high average IPV oSIA
needs, Fig. 5d also shows non-zero expected IPV needs
for oSIAs over the long-term at the 75th percentile. This
suggests a relatively high chance of some IPV oSIA
demand and the need to build a global IPV stockpile for
outbreak response, which could be operationalized as a
rotating IPV stock in the long-term IPV supply chain
[15], especially because mOPV represents an increas-
ingly risky oSIA option as the time since OPV cessation
increases and the mOPV stockpile will represent a finite
resource [16].
In the event of cumulative vaccine needs of more than
the currently planned 100 million filled mOPV doses,
the occurrence of any stock-outs depends on how
rapidly the mOPV demand unfolds and how long it
takes to convert bulk to filled mOPV (i.e., the filling
delay). Assuming a one year filling delay, we observed
stock-outs of at least one mOPV serotype in 27 of 100
iterations with the base case response strategy.
Figure 6 shows two examples of the potential conse-
quences of mOPV1 stockouts, both involving block-wide
oSIAs in response to iVDPV1 introductions in relatively
high-R0 blocks. In Fig. 6a, a stock-out occurs for the last
Fig. 5 Outbreak response supplemental immunization activity (oSIA) vaccine usage for the base case outbreak response strategy, based on 100
iterations with the global policy of at least 5 years of inactivated poliovirus vaccine (IPV) in all populations for 5 years after oral poliovirus vaccine (OPV)
cessation of the last serotype (note change in x-axis scales). a Summary statistics of serotype 1 monovalent OPV oSIA needs over time. b Summary statistics
of serotype 2 monovalent OPV oSIA needs over time. c Summary statistics of serotype 3 monovalent OPV oSIA needs over time. d Summary statistics of
IPV oSIA needs over time
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of 4 block-wide mOPV1 oSIAs because the estimated
total doses within the series of oSIAs over a period of
approximately 4 months exceeds 100 million. The stock-
out results in reduced coverage during the last oSIA,
and consequently the virus sustains a low level of trans-
mission until it leads to another outbreak peak the fol-
lowing year (dashed blue curve in Fig. 6a). This second
peak does not occur with an infinite stockpile (solid
black curve in Fig. 6a). With higher population immun-
ity to transmission during the second outbreak, the trig-
gered new mOPV1 oSIA series controls the outbreak.
The filled mOPV1 stock again goes to zero, but suffi-
cient bulk mOPV1 remains to replenish the stock and
no further mOPV1 oSIA demands occur before the filled
stock restores to 100 million mOPV1 doses. Due to a
small iVDPV1 outbreak in another subpopulation with
much lower R0, some more mOPV1 gets used before the
5-year mOPV1-use window closes, with little impact on
the filled mOPV1 stock. In contrast, in Fig. 6b, a second
outbreak peak occurs much sooner than after the initial
mOPV1 oSIA series failed to control the outbreak in
Fig. 6a. With unlimited filled mOPV1 available, the
Fig. 6 Two examples of model behavior with assumed unlimited vs. finite monovalent oral poliovirus vaccine (OPV) stockpile for the base case
outbreak response strategy and the global policy of at least 5 years of inactivated poliovirus vaccine in all populations for 5 years after oral poliovirus
vaccine (OPV) cessation of the last serotype. a Outbreak following a serotype 1 immunodeficiency-associated vaccine-derived poliovirus (iVDPV1)
introduction in a block with a basic reproduction number (R0) of 11, with stock-out resulting in a second outbreak wave but ultimate outbreak control.
b Outbreak following an iVDPV1 introduction in a block with an R0 of 12, with stock-out resulting in a failure to control the outbreak and an eventual
OPV restart (note change in y-axis scale)
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second series of oSIAs controls the outbreak (solid black
curve in Fig. 6b). However, with 100 million filled mOPV1
doses and a one year filling delay, the second oSIA series
cannot take place, leading to a very large outbreak in the
second year (dashed blue curve in Fig. 6b). The continuing
outbreak results in further stock-outs and an eventual
OPV restart when the outbreak spreads to other blocks.
Thus, an insufficiently large stockpile of readily available
vaccine can under some circumstances lead to very ser-
ious consequences and a failure to maintain a world free
of LPV transmission.
The last row of Table 3 shows that of the 27 iterations
with mOPV stock-outs, 5 resulted in new OPV restarts that
did not occur for the base case, which nearly quadruples
the average expected number of cases. Moreover, remark-
ably the delayed oSIAs associated with stock-outs resulted
in more mOPV demand and use, with a higher risk of
mOPV exportations and new iVDPV introductions.
Table 4 shows the number of iterations with more than
100 or 500 million cumulative stockpile doses and the
number of iterations with at least one expected mOPV
stock-out for all outbreak response choices considered.
Notably, extending mOPV use through Tend only resulted
in one additional stock-out because mOPV use beyond the
first 5 years remained relatively rare and successful in rap-
idly containing outbreaks. Using a greater geographical
scope naturally increased the stockpile vaccine needs and
number of stock-outs compared to the base case. More
surprisingly, reducing the scope also increased the number
of stock-outs. This occurred because an insufficiently large
scope can result in more subsequent outbreaks in other
subpopulations and blocks that then require more mOPV
oSIAs. Similarly, increasing the response time moderately
increased the number of stock-outs. Finally, we did not
record stock-outs for the alternative oSIA vaccine options
for serotype 2 outbreaks before OPV13 cessation because
of the changing vaccine over time. However, for IPV oSIAs,
we observed a very large number of iterations requiring at
least 100 million IPV doses because of the poor ability of
IPV oSIA to control the outbreaks and prevent further IPV
oSIA needs.
Discussion
This analysis highlights the existence of a large number
of outbreak response choices that influence the expected
polio cases, costs, and success of long-term poliovirus
risk management. OPV cessation will lead to unprece-
dented conditions that include increasing numbers of
individuals with no recent LPV exposure and lower
population immunity to transmission globally than ever
existed [17]. The global model suggests that we can
expect aggressive outbreak response to contain out-
breaks that may occur and to protect the achievement of
global polio eradication. After OPV cessation, outbreak
Table 4 Number of iterations with vaccine needs that exceed the expected stockpile doses for different outbreak response choices
Outbreak response choice Number of iterations that
require > 100 million doses
Number of iterations that
require > 500 million doses
Number of iterations with
expected mOPV stockout
mOPV1 mOPV2 mOPV3 tOPV IPV mOPV1 mOPV2 mOPV3 tOPV IPV mOPV1 mOPV2 mOPV3 Any
Base case 23 12 8 N/A 6 1 0 1 N/A 2 19 11 7 27
Duration of mOPV use after
homotypic OPV cessation (years)
- 3 20 11 7 N/A 17 0 0 1 N/A 11 18 11 7 27
- through Tend 24 12 9 N/A 1 0 1 1 N/A 0 19 11 8 28
Minimum R0 to trigger block-wide
response
- 8 32 18 14 N/A 8 2 0 1 N/A 3 28 16 13 44
- 13 20 11 11 N/A 6 2 0 1 N/A 3 17 9 11 30
Response delay (days)a
- Always 30 22 13 8 N/A 5 1 0 0 N/A 2 18 11 7 26
- Always 45 23 12 8 N/A 6 1 0 1 N/A 3 19 11 7 27
- Always 60 24 12 8 N/A 8 2 0 1 N/A 5 20 11 7 28
oSIA vaccine between OPV2 and
OPV13 cessation for serotype 2
outbreaks
- tOPV 23 0 8 11 6 1 0 1 0 2 N/A N/A N/A N/A
- IPV 23 12 8 N/A 21 1 0 1 N/A 3 N/A N/A N/A N/A
Abbreviations: IPV inactivated poliovirus vaccine, iVDPV immunodeficiency-associated vaccine-derived poliovirus, mOPV(1,2,3) monovalent OPV (serotype 1, 2, or 3,
respectively), OPV oral poliovirus vaccine, OPV## cessation globally-coordinated cessation of OPV containing the serotype(s) indicated by ##, oSIA outbreak
response supplemental immunization activity, R0 basic reproduction number, Tend end of the analytical time horizon (i.e., December 31, 2052), tOPV trivalent OPV
aAll alternative choices assume non-adaptive surveillance quality (detection threshold) and response delay in the event of a subpopulation-specific response
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virus exportations to other populations may much more
readily lead to new outbreaks than outbreak virus expor-
tations before OPV cessation, because of the decreasing
global population immunity to transmission. Conse-
quently, controlling outbreaks after OPV cessation re-
quires much more aggressive response than current
strategies. This includes high-quality surveillance to
avoid missing signals and rapidly confirm outbreaks to
minimize outbreak response delays. Delaying the
response time from 45 to 60 days more than doubled
the risk of uncontrolled outbreaks, which means that
failure to immediately respond with population-wide
vaccination to a signal while awaiting details about its
origin may lead to very serious consequences. Similarly,
particularly in high-risk populations, effective outbreak
response requires a large geographical scope, with little
expected effect of a local vaccination response given the
large number of asymptomatic poliovirus infections and
the ability of polioviruses to spread rapidly in the con-
text of low population immunity to transmission after
OPV cessation. In the same context, attempting to first
respond with IPV may not prevent further transmission
of the outbreak virus, as experienced after an initial IPV
response to a WPV1 detection in Israel [18, 19], making
ultimate control with OPV much more difficult and
risky.
Aggressive outbreak response can in some cases re-
duce the stockpile vaccine requirements by preventing
further spread that would require additional doses for
response. The global model suggests the currently
planned stockpile of 100 million filled and 400 mil-
lion bulk mOPV doses of each serotype will meet the
oSIA demand in over 50 % of the iterations. While
mOPV stored in frozen bulk remains stable for
decades, the shelf life of filled OPV products equals
2 years and at some point mOPV use after OPV ces-
sation poses a greater risk due to its potential export-
ation, which we assume occurs 5 years after OPV13
cessation. Thus, several hundreds of millions of OPV
doses (compared to a current annual OPV demand of
billions of doses) may remain unused. However, the
potentially very large human, financial, and political
consequences in the event of an insufficiently large
stockpile may justify some investment in a larger
stockpile than likely needed, even if it means eventu-
ally wasting some OPV. Similarly, mechanisms to
store larger amounts of bulk OPV or to maintain a
warm base of OPV production by using them as
Sabin IPV seed strains, which provide a safer option
for IPV production than WPV seed strains [2, 20],
may prove prudent for the eventuality of a need to
restart OPV use in most developing countries in the
event of a failure. Alternatively, we see real value in
efforts to ensure a shorter filling delay than 1 year in
an emergency situation, which would significantly
reduce the probability of stock-outs.
The global model suggests a relatively small risk of
exportations of mOPV used for oSIAs, even many years
after OPV cessation. Different assumptions about spread
between populations may increase this probability,
although our results thus far suggest that doing so would
disproportionately increase the risk of exporting the out-
break virus compared to mOPV viruses. The global
model assumes relatively closed subpopulations that
allow for selection of well-defined outbreak populations
that interact relatively little with other subpopulations.
Such clear-cut determination of a relatively closed target
population may not prove feasible in a real outbreak
situation. We do not account for the potential higher risk
of exporting mOPV at the edges of the outbreak response
than overall between populations, but this remains an
important topic of further research that could alter our
findings related to the duration of safe mOPV use. Simi-
larly, our deterministic model for die-out of transmission
may lead to die out of some effective exportations of
OPV-related virus before any significant OPV evolution
can occur, which represent a simplification of reality that
stochastic models could address more realistically. The
possibility of generating new long-term iVDPV excretors
due to mOPV use appears of some concern and reinforces
the current path of not using mOPV for longer than a few
years after OPV cessation. Balancing the risks associated
with mOPV use against the likely inability of IPV to
control outbreaks in settings conducive to fecal-oral trans-
mission [18, 19] remains an important challenge.
The results of this analysis depend on a number of pre-
viously explored and considered assumptions and limita-
tions of the poliovirus transmission and OPV evolution
model, which the global model carries forward into this
analysis [2, 9, 10, 12, 21, 22]. Besides the outbreak
response strategy itself, the rate of decrease in population
immunity with IPV-only routine immunization and the
assumed frequency of poliovirus exportations to other
subpopulations and blocks determine the ability to control
outbreaks and prevent mOPV from starting new VDPV
outbreaks. Other limitations include the conceptual
characterization of global variability using 710 subpopula-
tions and the simplified modeling constructs used to
simulate die-out, OPV evolution, waning of immunity to
transmission, and effective poliovirus introduction into
the deterministic poliovirus transmission and OPV evolu-
tion model [2, 12]. Moreover, the true prevalence of long-
term iVDPV excretors and other long-term risks remain
uncertain and effective polio antiviral drugs may offer a
tool to clear long-term iVDPV infections if given to both
paralytic and asymptomatic long-term iVDPV excretors
[2, 7, 23], including those infected before OPV cessation
or with mOPVs used for outbreak response. Other new
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technologies in the pipeline such as genetically stable
OPV vaccines, non-replicating IPV seed strains, or IPV
vaccines with enhanced ability to provide intestinal im-
munity may impact future risk and the options for out-
break response.
Given the uncertainty about the probability and con-
sequences of outbreaks after OPV cessation, all inter-
ventions to prevent or minimize the probability of
poliovirus reintroductions remain a priority (e.g., polio
antiviral drugs, non-replicating IPV seeds strains, high
bio-containment levels). Nevertheless, poliovirus reintro-
ductions will remain possible and this analysis clearly
demonstrates the importance of outbreak response and
stockpile preparedness to maximize the probability of
maintaining a polio-free world after OPV cessation.
Conclusions
Numerous outbreak response choices affect the prob-
ability of successfully managing poliovirus risks immedi-
ately after OPV cessation and in the long term. Speed
and quality of oSIAs unambiguously improve the ability
to manage risks, and stockpiling more vaccine than
expected for outbreak response appears a prudent
approach. While OPV appears the right choice to re-
spond to outbreaks with a few years of OPV cessation,
longer-term vaccine type decisions remains challenging
since OPV comes with VDPV risks while IPV comes
with high costs and no demonstrated ability to control
outbreaks in settings conducive to fecal-oral poliovirus
transmission. Outbreak response strategies and vaccine
choices will remain critical in the polio endgame.
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